Home / Technology & Devices (page 20)

Technology & Devices

Routine Blood Tests Can Help Measure A Patient’s Future Risk for Chronic Disease, New Study Finds

A new study by researchers at the Intermountain Medical Center Heart Institute in Salt Lake City finds that combining information from routine blood tests and age of primary care patients can create a score that measures future risk of chronic disease. This simple risk score, termed the Intermountain Chronic Disease …

Read More »

Allergan and Editas Announce CRISPR-Based Research and Development Deal for Rare Eye Diseases

DUBLIN and CAMBRIDGE, Mass., March 14, 2017 /PRNewswire/ — Allergan plc (NYSE: AGN), a leading global pharmaceutical company, and Editas Medicine, Inc. (NASDAQ: EDIT), a leading genome editing company, today announced that Allergan’s wholly-owned subsidiary, Allergan Pharmaceuticals International Limited, and Editas Medicine have entered into a strategic research and development alliance …

Read More »

Study Confirms Accuracy of OncoCyte’s Blood Test for Early Detection of Lung Cancer

ALAMEDA, Calif., March 06, 2017 (GLOBE NEWSWIRE) — OncoCyte Corporation (NYSE MKT:OCX), a developer of novel, non-invasive blood based tests to aid in the early detection of cancer, today reported the successful completion of a critical step in the development of its lung cancer diagnostic test. While the key performance …

Read More »

Exonics Therapeutics Launches with Funding from CureDuchenne to Advance CRISPR/Cas9 Therapy for DMD

BOSTON, Feb. 27, 2017 (GLOBE NEWSWIRE) — Exonics Therapeutics, Inc., a newly formed biotechnology company focused on developing gene editing technologies like CRISPR/Cas9 to permanently correct a majority of mutations causing Duchenne muscular dystrophy and other neuromuscular diseases, today announced a commitment of $5 million in seed financing from CureDuchenne …

Read More »

New Assay May Lead to a Cure for Debilitating Inflammatory Joint Disease

Current treatments for rheumatoid arthritis relieve the inflammation that leads to joint destruction, but the immunologic defect that triggers the inflammation persists to cause relapses, according to research conducted at NYU Langone Medical Center and the University of Pittsburgh. Known as autoantibodies and produced by the immune system’s B cells, …

Read More »

OncoSec’s ImmunoPulse Shows Treatment Effect in Phase 2 Melanoma Study

SAN DIEGO, Feb. 23, 2017 /PRNewswire/ — OncoSec Medical Incorporated (“OncoSec”) (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today reported new positive clinical data from a Phase II Investigator Sponsored Trial assessing the combination of OncoSec’s investigational intratumoral therapy, ImmunoPulse® IL-12, and the approved anti-PD- 1 therapy (pembrolizumab), …

Read More »

X-Chem Expands its Collaboration with Janssen in Inflammatory Diseases

WALTHAM, Mass.–(BUSINESS WIRE)–X-Chem, Inc. (X-Chem) announced today that it has expanded its collaboration with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to discover new drug leads for the treatment of inflammatory disease. The multi-target expansion builds on the parties’ existing discovery and license partnership, …

Read More »

Horizon Discovery Signs a Master Service Agreement with Top Three Pharma Company

Cambridge, UK, 14 February 2017: Horizon Discovery Group plc (LSE: HZD) (“Horizon” or the “Group”), the world leader in the application of gene editing technologies, today announces the signing of a Master Services Agreement (MSA) with a top three global pharmaceutical company (the “Company”), extending support for their drug discovery …

Read More »

Ferring Enters Exclusive Development and Option Agreement with Foresee Pharmaceuticals for its Peptide Therapeutic Platform

SAINT-PREX, Switzerland–(BUSINESS WIRE)–Ferring Pharmaceuticals and Foresee Pharmaceuticals Co., Ltd. (6576.TWO), announced today that the companies have entered into an exclusive worldwide development and option agreement to leverage Foresee’s proprietary and unique Stabilized Injectable Formulation platform (SIF) for the development of long duration, controlled release formulations of a peptide therapeutic. Under …

Read More »

Study Finds Genetic Profiling Can Guide Stem Cell Transplantation for Patients with Myelodysplastic Syndrome

A single blood test and basic information about a patient’s medical status can indicate which patients with myelodysplastic syndrome (MDS) are likely to benefit from a stem cell transplant, and the intensity of pre-transplant chemotherapy and/or radiation therapy that is likely to produce the best results, according to new research …

Read More »